574 related articles for article (PubMed ID: 28797845)
21. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
23. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
24. Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
Yoon S; Yang H; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Jung KH; Park SR; Choi EK; Kim SW; Park KS; Lee DH
Cancer Res Treat; 2022 Jul; 54(3):767-781. PubMed ID: 34607394
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
27. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
28. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
29. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
30. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
31. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
32. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
34. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
35. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
36. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
[TBL] [Abstract][Full Text] [Related]
38. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
[TBL] [Abstract][Full Text] [Related]
40. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Wang YQ; Shen AJ; Sun JY; Wang X; Liu HC; Zhang MM; Chen DQ; Xiong B; Shen JK; Geng MY; Zheng M; Ding J
Acta Pharmacol Sin; 2016 Dec; 37(12):1587-1596. PubMed ID: 27616574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
